rs2069526 — CYP1A2 -739T>G

Intronic CYP1A2 variant near the 5' end; G allele is associated with altered metabolic ratios for CYP1A2 substrates including escitalopram

See your personal result for CYP1A2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP1A2 -739T>G — A Secondary Intronic Variant in the Caffeine-Metabolizing Gene

CYP1A2 is the liver enzyme responsible for breaking down roughly 95% of caffeine, as well as several important medications including clozapine, theophylline, and escitalopram. The enzyme's activity varies substantially between individuals — up to 40-fold — driven by a combination of genetic polymorphisms, smoking status, and dietary factors. The rs2069526 variant (-739T>G) is an intronic change located near the 5' end of CYP1A2 11 HGVS: NM_000761.5:c.-10+103T>G; chromosome 15, GRCh38 position 74,748,999. Its G allele is rare globally (approximately 5–7%) and has been associated with differences in how certain CYP1A2 substrates are cleared, though its independent functional effect remains less clearly established than the better-studied rs762551 (*1F) variant.

The Mechanism

As an intronic variant, rs2069526 does not alter the amino acid sequence of the CYP1A2 protein. Instead, it may influence 22 gene expression: how much of the enzyme protein is made in liver cells or splicing efficiency. Intronic variants near exon-intron boundaries or regulatory regions can create or disrupt binding sites for splicing factors or transcription regulators. The -739 position places this variant upstream of the main coding region, where it could modulate basal or inducible transcription in conjunction with other haplotype-defining SNPs.

The Evidence

A pharmacogenomics study of 158 Taiwanese patients receiving escitalopram33 pharmacogenomics study of 158 Taiwanese patients receiving escitalopram
Kuo HW et al. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics, 2013 found that rs2069526 was significantly associated with the S-DDCIT/S-DCIT metabolic ratio at week 2 (p = 0.018). Individuals with G alleles — which correlated with elevated metabolic ratios — experienced more pronounced adverse effects early in treatment. Notably, CYP2C19 is the primary pathway for escitalopram; this finding suggests rs2069526 may tag a CYP1A2 haplotype that modulates a secondary metabolic route or reflects linkage disequilibrium with a functionally important variant.

A meta-analysis of lung cancer risk44 meta-analysis of lung cancer risk
Bu ZB et al. Four polymorphisms in CYP1A2 and lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 2014 pooled five studies (657 cases, 984 controls) and found no significant association between rs2069526 and lung cancer risk. A Swedish-Korean comparison study55 Swedish-Korean comparison study
Ghotbi R et al. CYP1A2 genetic polymorphisms, enzyme activity and genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol, 2007 found no significant genotype-phenotype relationship for the -739T>G variant alone, while confirming that the related rs762551 (*1F) allele was associated with higher enzyme inducibility in smokers. Together, the evidence suggests rs2069526 may have limited independent functional significance but could be part of a haplotype block tagging broader CYP1A2 activity differences.

Practical Actions

Because this variant is in the same gene as the well-characterized rs762551 (*1F), individuals carrying the G allele at rs2069526 should be aware that CYP1A2 activity in their case remains less predictable from this single variant alone. For medications processed primarily by CYP1A2 — particularly clozapine, theophylline, and tizanidine — therapeutic drug monitoring is the most reliable approach rather than genotype-directed dosing from this marker alone. Smoking is the dominant environmental regulator of CYP1A2 and can increase enzyme activity by two- to three-fold, outweighing most genetic effects; changes in smoking status during CYP1A2-substrate treatment require dose re-evaluation.

Interactions

rs2069526 was found to be significantly associated with escitalopram metabolic ratios in the same study that identified rs2069521 and rs4646425 (Kuo et al., 2013). These variants may act in concert as a haplotype, meaning the observed escitalopram association may reflect combined haplotype effects rather than the action of rs2069526 in isolation. The rs762551 (*1F) variant at the same locus has substantially stronger and better-replicated evidence for affecting CYP1A2 inducibility, caffeine clearance, and cardiovascular risk from coffee.

Drug Interactions

escitalopram dose_adjustment literature
caffeine dose_adjustment literature
clozapine dose_adjustment literature
theophylline dose_adjustment literature

Nutrient Interactions

caffeine altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

TT Common Genotype Normal

Common CYP1A2 -739T>G genotype

You carry two copies of the T allele at rs2069526, the common genotype found in approximately 86% of people globally. This is the reference allele at this position in the CYP1A2 gene. There is no evidence that this genotype is associated with meaningfully altered CYP1A2 enzyme activity compared to the general population for this specific variant, though your overall CYP1A2 activity is still shaped by other variants in the gene (especially rs762551), smoking status, and dietary factors.

GT G Allele Carrier Intermediate

One copy of the CYP1A2 -739G allele

The -739T>G change is located in the 5' intronic region of CYP1A2 (HGVS: NM_000761.5:c.-10+103T>G) and does not alter the protein sequence. The Kuo et al. (2013) study found significant association with escitalopram metabolic ratios among 158 patients, though escitalopram is primarily metabolized by CYP2C19, suggesting rs2069526 may be tagging a haplotype rather than acting as a primary functional variant. The Swedish-Korean study (Ghotbi et al., 2007) found no significant individual phenotype difference for -739T>G, and no ClinVar pathogenicity classification has been assigned.

GG Homozygous G Homozygous

Two copies of the CYP1A2 -739G allele — rare genotype

At a global G allele frequency of approximately 6%, the GG genotype (q²) would be expected in only about 0.3-0.5% of individuals under Hardy-Weinberg equilibrium. No published study has characterized this genotype specifically. The best available data come from the Kuo et al. (2013) study of 158 patients, which found the G allele overall (TG + GG) associated with altered escitalopram metabolic ratios. Given the rarity of GG, it is important to combine this finding with the better-studied rs762551 (*1F) result for a more complete picture of CYP1A2 metabolizer status. CYP2C19 genotype remains the primary pharmacogenomic driver for escitalopram.